BLUEBIRD BIO INC's ticker is BLUE and the CUSIP is 09609G100. A total of 178 filers reported holding BLUEBIRD BIO INC in Q1 2023. The put-call ratio across all filers is 0.92 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $106,115 | +15.8% | 34,906 | +25.3% | 0.00% | – |
| Q2 2023 | $91,614 | -1.3% | 27,847 | -4.7% | 0.00% | – |
| Q1 2023 | $92,859 | -77.6% | 29,231 | -51.3% | 0.00% | -100.0% |
| Q4 2022 | $415,388 | +196.7% | 60,083 | +170.5% | 0.00% | – |
| Q3 2022 | $140,000 | +57.3% | 22,208 | +3.8% | 0.00% | – |
| Q2 2022 | $89,000 | -95.2% | 21,387 | -1.3% | 0.00% | -100.0% |
| Q1 2022 | $1,871,000 | +939.4% | 21,676 | +20.0% | 0.00% | – |
| Q4 2021 | $180,000 | -35.0% | 18,058 | +24.4% | 0.00% | -100.0% |
| Q3 2021 | $277,000 | -29.2% | 14,515 | +18.4% | 0.00% | 0.0% |
| Q2 2021 | $391,000 | +9.8% | 12,256 | +4.1% | 0.00% | 0.0% |
| Q1 2021 | $356,000 | -25.1% | 11,778 | +7.3% | 0.00% | 0.0% |
| Q4 2020 | $475,000 | -14.9% | 10,979 | +4.5% | 0.00% | -50.0% |
| Q3 2020 | $558,000 | +6.3% | 10,503 | +23.3% | 0.00% | 0.0% |
| Q2 2020 | $525,000 | +37.1% | 8,520 | +2.7% | 0.00% | 0.0% |
| Q1 2020 | $383,000 | – | 8,298 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Sessa Capital IM, L.P. | 1,834,965 | $35,066,000 | 1.72% |
| Birchview Capital, LP | 84,000 | $1,605,000 | 1.09% |
| ARMISTICE CAPITAL, LLC | 2,472,000 | $47,240,000 | 0.80% |
| EcoR1 Capital, LLC | 802,507 | $15,336,000 | 0.53% |
| Parametrica Management Ltd | 36,919 | $706,000 | 0.53% |
| Bain Capital Life Sciences Investors, LLC | 538,179 | $7,239,000 | 0.45% |
| APPLETON GROUP, LLC | 19,495 | $373,000 | 0.32% |
| MANGROVE PARTNERS IM, LLC | 175,587 | $3,355,000 | 0.30% |
| Quinn Opportunity Partners LLC | 230,100 | $4,397,000 | 0.28% |
| PDT Partners, LLC | 171,700 | $3,281,000 | 0.24% |